Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies
Latest Information Update: 18 May 2025
At a glance
- Drugs Nipocalimab (Primary)
- Indications Neonatal alloimmune thrombocytopenia
- Focus Registrational; Therapeutic Use
- Acronyms FNAIT; FREESIA-1
- Sponsors Janssen Research & Development
Most Recent Events
- 19 Nov 2024 According to a Johnson & Johnson media release, an overview of an ongoing Phase 3 FNAIT clinical study design will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10.
- 01 Oct 2024 Planned initiation date changed from 23 Sep 2024 to 1 Oct 2024.
- 12 Sep 2024 Planned initiation date changed from 22 Jul 2024 to 23 Sep 2024.